Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy Amgen today announced detailed outcomes from the Phase 3 ‘181’ trial evaluating Vectibix) in combination with FOLFIRI , while a second-collection treatment for metastatic colorectal malignancy . In this trial, Vectibix significantly improved progression-free survival in patients with KRAS wild-type mCRC. These outcomes were presented at the 2009 2009 ECCO 15 – 34 European Multidisciplinary Congress in Berlin ESMO, Germany tadalafil generic india click here . The addition of Vectibix to FOLFIRI significantly improved median PFS by 8 weeks therapy such as rash, diarrhea, and hypomagnesemia.

The businesses’ combined commercialization actions will expand access to denosumab, once approved, to patients worldwide who are afflicted by osteoporosis and other bone loss circumstances. Our collaboration with GlaxoSmithKline can help Amgen bring the guarantee of denosumab to individuals in European countries and other parts of the world better than if we commercialized the drug globally on our own, stated Amgen CEO Kevin Sharer. Amgen and GlaxoSmithKline together are uniquely positioned to help medical providers and individuals understand the clinical promise and economic value of denosumab. This pioneering treatment that Amgen is rolling out will be a strong addition to your biopharmaceuticals portfolio, commented Andrew Witty, CEO of GlaxoSmithKline.